Boeing secures $883 million Army contract for cargo support services
SOUTH SAN FRANCISCO - CERo Therapeutics Holdings, Inc. (NASDAQ:CERO), a clinical-stage biotech company with a market capitalization of $2.3 million specializing in engineered T cell immunotherapies, announced the issuance of additional Series D Preferred Stock to certain institutional investors. The company’s stock currently trades at $0.43, near its 52-week low of $0.40. This move comes as a follow-up to an agreement dated April 22, 2025, involving the sale of Series D Preferred Stock for a total of up to $8 million. The company had previously issued $5 million worth of stock in April and has now raised an additional $750,000, with the possibility of raising up to $2.25 million more if the investors choose to fund further.
The newly issued shares are convertible into common stock. CERo’s CEO, Chris Ehrlich, expressed gratitude for the continued investor support, which aligns with the company’s progress in its clinical trials. According to InvestingPro data, while the company maintains more cash than debt on its balance sheet, its current ratio of 0.73 indicates potential liquidity challenges ahead. CERo recently achieved a milestone with the first human dosing of CER-1236, a novel CAR-T therapy candidate targeting TIM 4L for Acute Myeloid Leukemia (AML).
The proceeds from this offering are earmarked for advancing CERo’s clinical programs, particularly following two recent FDA Investigational New Drug (IND) allowances for trials in liquid and solid tumors. With an EBITDA of -$16.35 million in the last twelve months, this funding comes at a crucial time. InvestingPro subscribers have access to 13 additional key insights about CERo’s financial health and growth prospects. The funds will also support the activation of new clinical trial sites, including the MD Anderson Cancer Center (MDACC), and the introduction of additional sites.
CERo’s proprietary platform aims to create Chimeric Engulfment Receptor T cells (CER-T), which are designed to harness both innate and adaptive immune responses to target cancer. The company believes this approach may have broader applications than current CAR-T therapies, potentially addressing both hematological malignancies and solid tumors.
The press release emphasizes that this announcement does not constitute an offer to sell securities and that the securities will not be sold in any jurisdiction where such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
The forward-looking statements included in the press release reflect the company’s current expectations and projections about future events and are subject to risks, uncertainties, and assumptions. Investors should note that CERo is scheduled to report its next earnings on August 14, 2025, which could provide crucial updates on the company’s financial position and clinical progress. These statements are not guarantees of future performance and involve known and unknown risks, which could cause actual results to differ materially from those expressed or implied by these statements.
This news is based on a press release statement from CERo Therapeutics Holdings, Inc.
In other recent news, CERo Therapeutics Holdings, Inc. announced significant advancements in its intellectual property and clinical trial efforts. The company has expanded its patent portfolio with the granting of two U.S. patents and the allowance of a European patent application, strengthening its position in engineered T cell therapeutics. These patents cover the design and use of CER-1236, CERo’s lead compound, and extend the company’s protection until 2042 in the United States. Additionally, CERo has initiated a Phase 1 clinical trial for CER-1236, targeting acute myeloid leukemia (AML), with the first patient now undergoing treatment. This trial aims to determine the maximum tolerated dose and evaluate the safety and preliminary efficacy of the therapy.
Maxim Group has initiated coverage on CERo Therapeutics with a Buy rating and a price target of $3.00, citing the potential of CERo’s innovative technology in treating both liquid and solid tumors. The company’s compliance with Nasdaq’s minimum stockholders’ equity requirement was also recently regained, following financial maneuvers, including a private placement of Series D Preferred Stock. CERo’s CEO, Chris Ehrlich, emphasized the importance of these developments in advancing the company’s lead program, CER-1236. The company continues to focus on developing T cell therapies that integrate features of innate and adaptive immunity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.